SEP 17th OUTPERFORM $52 TARGET New drugs should give the stock a boost, Uhl said. Before the end of this year, he expects the Food and Drug Administration to approve two hypertension treatments from Forest, Azor and Nebivolol. The company should also file an application for its drug milnacipran as a treatment for fibromyalgia.
Results from clinical studies of a lung cancer drug candidate and a schizophrenia candidate should also lift Forest shares in the coming months, he said.
And this analysis didn't even include the acceleration of development due to success of inhaled aclidinium announced today. Aclidinium still in the farther future but getting positive results in testing prior to FDA NDA. Payoff in drug investment doesn't wait until it's "OUT OF THE BARN" after FDA approval, it's an investment in development which can happen at any day in the future depending on research success, which Forest definately has a handle on with it's varied and productive partners.